NCT00030667: Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood |
|
|
| Completed | 2 | 100 | US | imatinib mesylate, CGP 57148, Gleevec, Glivec, laboratory biomarker analysis, pharmacological study, pharmacological studies | National Cancer Institute (NCI) | Childhood Desmoplastic Small Round Cell Tumor, Childhood Synovial Sarcoma, Gastrointestinal Stromal Tumor, Lung Metastases, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma | 12/05 | 12/05 | | |
| Completed | 1/2 | 9 | Europe | Imatinib mesilate, STI571 | Novartis Pharmaceuticals | Refractory Desmoplastic Small Round Cell Tumors | 06/09 | | | |